Mestinon

Pyridostigmine bromide, the active ingredient in Mestinon, is a cholinesterase inhibitor presented as a tablet for oral use. It treats myasthenia gravis, helps resolve postoperative ileus, and is employed to reverse neuromuscular blockade after surgery. GNH USA supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mestinon is a cholinesterase inhibitor used in several neuromuscular and gastrointestinal conditions.

- Myasthenia gravis: improves muscle strength by increasing acetylcholine at the neuromuscular junction. - Postoperative ileus: accelerates the return of bowel motility after abdominal surgery. - Reversal of neuromuscular blockade: counteracts the effects of non‑depolarizing muscle relaxants used during surgery.

Mestinon may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Abdominal cramps - Diarrhea - Nausea - Increased salivation - Sweating - Muscle twitching

Serious or Rare Side Effects: - Bronchospasm - Severe bradycardia - Cholinergic crisis (muscle weakness, respiratory failure) - Allergic reactions such as rash or anaphylaxis

Before prescribing Mestinon, clinicians should consider several safety measures.

- Renal impairment: adjust dose because the drug is renally excreted. - History of asthma or COPD: monitor for bronchospasm. - Mechanical intestinal obstruction: avoid use as it may worsen obstruction. - Concomitant anticholinergic medications: assess for reduced efficacy. - Cardiac conditions: watch for bradyarrhythmias. - Store at below 25°C: keep in the original pack, protect from moisture.

Mestinon can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Non‑depolarizing neuromuscular blockers (e.g., vecuronium) – may reduce their effect. - Anticholinergic agents (e.g., atropine) – may antagonize therapeutic action. - Beta‑blockers – can enhance bradycardia. - Aminoglycoside antibiotics – may potentiate neuromuscular blockade.

Moderate Interactions (Monitor Closely): - Diuretics – may increase pyridostigmine plasma levels. - Cardiac glycosides – heightened risk of bradycardia. - Other cholinesterase inhibitors – additive cholinergic effects.